Register to learn more about investing!

* indicates required
June 16, 2021

8 Things to Know about Teladoc Health Before Investing in the Company

Register to get the latest investor tips

Register Now

Teladoc Health (TDOC) is a growing player in the telehealth space. As remote work and social distancing become the new normal, Teladoc health is poised to make a big move at significant scale advantages compared to its competitors.

Teladoc was in this space before the pandemic, and they already know their way around. The next steps they will take will allow huge opportunities to upsell current clients and improve margins.

Additionally, a proposed merger with Livongo will expand their capabilities and create a differentiated product that cannot be matched by competitors in the same space.

Business Facts for Teladoc Teladoc (NYSE:TDOC) is currently the largest telehealth provider that exists in the United States.

They have 52 million paying members and more than 22 million fee-only individuals among their membership. This a firm that utilizes a B2B model, and this gives them access to thousands of clients. Their clientele includes health plans, employers, hospitals, and complete health systems.

Teladoc currently has 40% of the Fortune 500 among its clientele, and these members provide employees with access to the platform. This means that in 2020, Teladoc was able to conduct 10.5 million virtual visits. This is the majority of their revenue at 79%. This is a huge part of the market and worth some notice!

Stethoscope with icon medical on tablet and wooden table background

Clients pay for the service as a pay-per-member-per-month model and they enroll monthly for a fee.

The rest of their revenue comes to them through visit fees and through other D2C partners like BetterHelp, which offers mental health services to Teladoc members.

This is a really unique and totally flexible means to leverage this model, and they have 55,000 licensed physicians across the world who are connected to them. This means that 450 medical specialties are available to members across the platform!

With their exciting connection to Livongo, they are working on “whole-person-care” which really speaks to people and feels far more personal than the take-a-number-and-sit-down model of regular healthcare.

I don’t know about you, but I really hate sitting in a doctor’s office waiting for my 15 minutes of some random doctor’s time, so this feels like a big step up in the world. Especially if you just have the sniffles! It would be nice to conduct more of my doctor’s visits this way…from the comfort of my own home!


Register to get the latest investor tips

Register now

Teladoc is Available and Low-Cost

What other healthcare provider can you say that about? This is the strength of this model, and it is the reason that the firm has a lead on over offerings in the same space. This model allows users to bypass their healthcare provider locally and choose their own provider and what care they are requesting!

Healthcare has too long been under the control of everyone but the patient, and this is why this company deserves some notice and to be taken seriously as a big player in the post-pandemic world.

The cost for this kind of healthcare access is minimal compared to in-office visits, and this makes telehealth a means for everyone to get access to healthcare, which is supposed to be the goal of everyone.



Post-Pandemic Growth Sure to Come

So, should you invest in Teladoc? Well, let’s talk about some facts related to the pandemic. First of all, after the opening months of the COVID-19 lockdown/crisis, telemedicine visits rose by 22.5%. This is compared to 2015 numbers. Yes, believe it or not, this super-easy way of seeing a doctor has been around that long but not everyone knew about it.

The estimated CAGR for the next 3 years is 40.4%, and there should be around a $250 billion opportunity to virtualize healthcare everywhere. This set of changes has created a sticky customer base who are eager for even more restrictions to ease and to make in-person-only healthcare a thing of the archaic past.

94% of Medicare advantage plans are stating that they will offer telehealth benefits to members in 2021, which is a big uptick compared to the 58% in 2020.

On the Teladoc side of things, this means that their 2.5 million Medicare Advantage members were on to something well before everyone else knew that this was possible.

Client retention in this space for Teladoc is currently sitting at 90%, which is massive for any healthcare offering that is based on a monthly fee.

CMS Adds Benefits for Medicare Visits

As I have said all along, Teladoc already practically owning this space has given them great advantages as the pandemic stretches out. CMS announced that they would pay physicians more for telehealth visits to their Medicare and Medicaid patients than they would for in-person visits

If this doesn’t cement the future of Teladoc, I don’t know what else will! This is huge for a set of insurance options that have traditionally been refused at many for-profit healthcare locales, and this makes healthcare available to millions of people who would otherwise not have access to it.

Beyond the social implications and the justice of this change, there are so many more people who can now get easy and quick medical care, and their doctors will be motivated to give it to them now that they will be paid fairly. This is a social justice that has been done, as well as a good sign for the long-term health of Teladoc itself.


Register to get the latest investor tips

Register Now

Not Only Check-Up Visits

As further evidence that Teladoc is going to go the distance, they are also offering dermatology and behavioral health services. You can get help with a cold or a mental health check now.

You can also get specialist care in a variety of other fields, which means that you don’t have to stop seeing your doctor for specialty visits despite the social distancing norm.

Even doctors did not believe that this model for care would work so well, and they are just now starting to come around as an industry and view these jobs and companies like Teladoc as viable healthcare entities. This can only mean growth for the future and stability long-term.

The 10 million visits in 202 made utilization jump from 9.3% to 16%. Teladoc is estimating that they will see a TAM of $121 billion after the Livongo merger. They are the oldest Telehealth company in the US, having been in this space since 2002.

They already have the foundation for basic healthcare sorted and off and running. Now they are just providing added value through all these specialty care options and the total-person healthcare viewpoint that speak well to patients.

Cross-Sell Opportunities

Teladoc is uniquely placed to complete other mergers after the Livongo merger is completed. They have the AI in place to make this process smooth, seamless, and beneficial to members.

They are the only platform to offer continuous monitoring and treatment for their members, and they show no signs of slacking on this promise. The whole-person care goal they have set is a unique and totally integrated model that is superior to traditional care models.

Livongo has a higher PMPM fee, so Teladoc is already adding value to their members by making this a part of their own monthly member fee without added cost. This is one of the major advancements that Teladoc can offer up with future merger choices.

This current merger is seeking to bring in a further 65 million potential users. This is the metric that is typical with a properly handled merger of these kinds of PMPM entities, and Teladoc has made it clear that they are willing to consider other mergers that will provide cross-benefits to members.

This type of growth is a savvy investor’s dream, and you won’t see a better company in this space for this kind of exponential growth opportunity.

Teladoc Leads the Way

Teladoc is clearly the leader in its space, and it will continue to be unless something changes significantly. Leveraging 20 years of prior experience, they are carving out a unique and authoritative healthcare option in exchange for a small monthly fee.

Our increasingly online lifestyle in the US makes this the best time ever to invest in these kinds of companies, and Teladoc is a Rockstar in its space. With added value growth on the horizon through mergers with companies like Livongo, it’s almost like you are investing in both companies for the price of one stock.

Teladoc is a giant that is on the rise, and investing in them at this stage of the game will secure investors the chance to reap the benefits of the healthcare industry as it is growing into this space. This is a growing industry, and there is no better way to get involved at the beginning of a global movement that is revolutionizing healthcare world-wide.

Be the first to find out what the Nose knows.

Sign up for the TraderNose Newsletter to stay up to date on Teladoc Health and other commonly-discussed small-cap stocks.


Read full disclaimer here.

Disclaimer

TraderNose profiles are not a solicitation or recommendation to buy, sell or hold securities. TraderNose is a paid advertiser and is not offering securities for sale. Neither TraderNose nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by TraderNose its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.

TraderNose does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.

Information presented by TraderNose may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

THIS SITE IS PROVIDED BY TraderNose ON AN “AS IS” AND “AS AVAILABLE” BASIS. TraderNose MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.
TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, TraderNose DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. TraderNose DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM TraderNose ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. TraderNose, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.
By using TraderNose, you agree, without limitation or qualification, to be bound by, and to comply with, these Terms of Use and any other posted guidelines or rules applicable.
The website contains links to other related World Wide Web Internet sites and resources. TraderNose is not responsible for the availability of these outside resources, or their contents, nor does TraderNose endorse nor is TraderNose exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall TraderNose be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.
You agree to indemnify and hold TraderNose, its officers, directors, owners, agents and employees, harmless from any claim or demand, including reasonable attorneys fees, made by any third party due to or arising out of your use of the website, the violation of these Terms of Use by you, or the infringement by you, or other user of the website using your computer, of any intellectual property or other right of any person or entity. We reserve the right, at our own expense, to assume the exclusive defense and control of any matter otherwise subject to indemnification.

TraderNose is owned and operated by Pulp and Fiber Inc., which is a Canadian based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, TraderNose.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and/or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign.

Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign.

The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. The Information we publish is based solely on Information provided to us by the Profiled Issuers. We do not conduct any independent research on Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and/or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.

All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.

We publish information about Profiled Issuers because we are compensated to advertise them and not for any other reason. Publishing of information does not constitute a stock “pick” by analyst. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.

The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.

We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.

There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.

We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.

We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.

We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and/or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.

We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information. This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. Our compensation is set forth below. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.

You acknowledge that any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.

We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.

If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.

The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.

The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.

You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.

When 3rd parties that hire us acquire, purchase and/or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.

The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.

We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.

If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.

If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.

The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.

TraderNose, reserves the right, at its sole discretion, to change, modify, add and/ or remove all or part of this Disclaimer and / or Terms of Use at any time.

We have been compensated by Profiled Issuers are follows: